The firm will build liquid biopsy companion diagnostic tests that complement its tissue-based assays and are tailored for drugs developed by pharma partners.
Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.
For the three months ended Jan. 31, the firm said revenues rose to $1.55 billion from $1.36 billion a year ago, beating analysts' average estimate of $1.44 billion.
Qiagen discussed what's in store after a failed bid by Thermo Fisher Scientific, and COVID-19 remained a hot topic on the second day of the virtual conference.
